Affymax (OTC: AFFY)
Affymax Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Affymax Company Info
Affymax, Inc. is a biopharmaceutical company. It is engaged in the developing of nephrology and specialty care space by delivering innovative therapeutical offerings to patients and healthcare providers. The company was founded on July 20, 2001 and is headquartered in New York, NY.
News & Analysis
The Nasdaq's 5 Most Hated Stocks
The Nasdaq hasn't had a down month this year, but that's not stopping skeptics from piling onto these five companies.
3 Reasons Investors Are Scared of Biotech Stocks
There's more than one way to see monster drops.
5 of Last Week's Biggest Losers
These five companies went the wrong way this past week.
3 Ways You Can Be a Successful Biotech Investor
Following these key steps will allow you to participate in what could be the greatest growth sector over the next decade.
Pharmaceuticals: Just What the Dow Ordered
Though it's had a few down days, the Dow is on a big upswing and big pharma is right alongside it.
Down 60%: Affymax Cuts to the Bone
Remember, investors, don't count those mysterious biotech pops before actual news confirms it.
3 Can't-Miss Health-Care Events This Week
Three earnings reports set the stage for an otherwise quiet week in the health-care sector.
Steer Clear of Affymax's Mysterious Pop
This is a rocket ride you want no part of.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.